Benjamin L Basil
Benjamin L Basil was appointed as President & General Manager Australia, New Zealand and North Asia Pacific in January 2019.
As a global executive leader with over 20 years’ experience in the pharmaceutical industry, Benjamin is passionate about healthcare and creating exceptional customer experiences.
Prior to relocating to Australia, Benjamin held several senior roles at Eli Lilly and Company in the United States, in the areas of oncology and neuroscience.
Benjamin is passionate about selecting the right people and building a high performing team that lives by Lilly values. He is an advocate for Lilly’s Diversity & Inclusion efforts, in particular the focus on psychological safety and wellbeing of employees.
Salvador Manuel Garcia De Quevedo Perez
Salvador joined Eli Lilly Australia and New Zealand in May 2020. He began his Lilly career as a Clinical Research Associate in Lilly Mexico, and over his 25-year career, made significant impacts for patients across the world in a variety of roles across Brazil, Turkey and the UK before relocating to Indianapolis, U.S.
In the U.S., Salvador served as a leader for the emerging markets and biomedicine’s Medical Affairs. In 2018, Salvador joined Global Regulatory Affairs and led the regulatory organisation through several high-value diabetes submissions and approvals.
Ping Fu - Chief Financial Officer
Melanie Field - Autoimmune Business Leader
Gabrielle Reppen - Chief Operations Officer
Martin Hayes - Sales Director
Jamie Preston - Senior Director Human Resources
Gabi Mittas - Chief Marketing Officer
Margaret Pereira - Ethics & Compliance Director
Anne Sinclair - General Counsel
Peter Vermeer - Senior Director Corporate Affairs & Market Access
Darran Forsyth - IDS Business Partner & NGCE Capability Leader